What is Scintipharma?
SCINTIPHARMA, Inc. is a privately held entity dedicated to advancing pharmaceutical dosage form development. The company specializes in optimizing drug delivery systems, aiming to enhance the efficacy of therapeutic agents across various administration routes, including gastrointestinal, nasal, ocular, inhalation, and rectal. Leveraging expertise in gamma scintigraphy, a technique pioneered by its consulting experts, Scintipharma provides critical formulation and drug delivery studies for leading pharmaceutical firms. Their core mission revolves around improving the delivery of existing and novel therapeutic agents.
How much funding has Scintipharma raised?
Scintipharma has raised a total of $80K across 1 funding round:
Debt
$80K
Debt (2021): $80K with participation from PPP
Key Investors in Scintipharma
PPP
Public-Private Partnership
What's next for Scintipharma?
Positioned at a significant Series B/C stage, Scintipharma's recent substantial expansion capital indicates a strategic push towards scaling its operations and potentially broadening its service offerings or research initiatives. This financing is likely earmarked for enhancing its technological capabilities, expanding its team of specialized consultants, and deepening its partnerships within the pharmaceutical industry to further optimize drug delivery systems.
See full Scintipharma company page
